Can we actually live forever?

Ask most scientists if humans can live forever and you'll get a careful answer about hallmarks of aging and healthspan. Ask the people funding the research, and you often get something much less careful.

Larry Ellison, Oracle's co-founder, has been blunt about this for decades. In a widely cited profile, he put it this way: "Death has never made any sense to me. How can a person be there and then just vanish, just not be there?" He's backed anti-aging research directly for years on the strength of that discomfort.

Peter Thiel has said similar things without much hedging. He's described the acceptance of death as a kind of learned helplessness, and has been open that his interest in funding longevity science — including early backing of SENS Research Foundation — comes from actually wanting to beat it, not just study it philosophically.

Bryan Johnson has taken it furthest into public spectacle. His "Blueprint" protocol — a fully published, obsessively tracked regimen of supplements, exercise, and biomarker testing — exists explicitly to slow his own aging as measurably as possible, and he's said outright that he considers death optional rather than inevitable. Whatever you think of the method, he's not implying it. He's saying it, on camera, repeatedly.

Ray Kurzweil has been making a related bet for longer than almost anyone: that medicine will improve faster than we age, a concept he calls "longevity escape velocity" — essentially, staying enough steps ahead of decline that you arrive at each new treatment while you're still around to use it.

This site isn't going to tell you any of them are right. Nobody has extended maximum human lifespan yet, and "I believe it" from a billionaire isn't clinical evidence. What we will tell you is that these aren't fringe cranks — they're people directing genuinely enormous capital into aging research specifically because they believe this, which is exactly why the science has moved as fast as it has over the last decade.

Here's the part that matters more than any individual quote: even where the science is real and published, it isn't equally available. Most primary research still sits behind journal paywalls that can run $30-50 per paper — a real barrier if you're not affiliated with a university. Positive trial results get published far more reliably than negative ones, which quietly skews the public picture of what's actually working. And when something does get proven, patents typically keep it priced out of reach for years before it's ever affordable at scale. The concierge protocols, the personalized biomarker panels, the off-label drug access the people above actually use — those are gated by cost today, full stop, regardless of how closely you follow the research.

That's the honest version of "they have something you don't": not a secret, but a price tag. The rest of this site exists to close the part of that gap that's actually closable — understanding what's real, what's hype, and what's worth watching next — for free. What comes after that is what Insider is for.